Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

The medtech industry hopes to capitalise on increased awareness about the obesity space to promote multidisciplinary ...

Unfortunately, too many insurers — including Medicare — still see obesity as a cosmetic issue instead of the disease that it ...

Australian researchers said that supervised diets with intermittent fasting were for children with serious health conditions, ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

A new type of blood test using lipids could make it easier to identify children at risk of complications around obesity ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Rochester Institute of Technology Assistant Professor Nourridine Siewe receives award for mathematical modeling research ...